Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 164 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo topical gel Clear all
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

NCT02271854
View directory record Official record
Conditions
Muscle Soreness
Interventions
Diclofenac sodium gel 1%, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 35 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

NCT01568489
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
HL-009 Liposomal Gel, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Arlington Heights, Illinois • Fridley, Minnesota • Berlin, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain

NCT01255423
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac sodium topical gel 1%, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Birmingham, Alabama • Aventura, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hypertrophic Scar Prevention by Novel Topical Gel Application

NCT03403621
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
Pentamidine Isethionate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Sep 30, 2026, 8:34 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

NCT05276401
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis

NCT03400475
View directory record Official record
Conditions
Peri-implant Mucositis
Interventions
Simvastatin, Placebo
Drug · Other
Lead sponsor
Ahmed Mohamed Mahrous
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

NCT00266669
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2007 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of UC-781 Vaginal Microbicide

NCT00132444
View directory record Official record
Conditions
HIV Infections
Interventions
topical vaginal application of UC-781 gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 (naftin 2 % gel), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

NCT01556932
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
ABH gel, placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
baclofen/amitriptyline/ketamine gel, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
165
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers

NCT00764361
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
doxycycline, placebo gel
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

NCT00695565
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Placebo Gel, Clonidine Topical Gel (ARC-4558)
Drug
Lead sponsor
Arcion Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Sep 30, 2026, 8:34 AM EDT
Recruiting Phase 1 Interventional

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

NCT06504160
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 30, 2026, 8:34 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Sep 30, 2026, 8:34 AM EDT